DRKS00017255已完成2 期
A single arm phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in combination with cetuximab in subjects with unresectable stage III or stage IV cutaneous squamous cell carcinoma (cSCC) - AliCe (Avelumab in combination with cetuximab)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Alcedis GmbH
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Patients may be included in the study only if they meet all the following criteria:
- •Male or female subjects aged = 18 years on day of signing informed consent
- •Histologically proven cSCC in stage III, not amenable to surgery / curative radiation, or stage IV (according to the 8th AJCC edition; see chapter 18.6)
- •ECOG performance status of 0 or 1
- •Measurable disease, i.e. at least one measurable lesion per RECIST, v1.1
- •Required values for initial laboratory tests:
- •o Absolute neutrophil count (ANC) = 1.5 × 109/L
- •o Platelet count = 100 × 109/L
- •o Hemoglobin = 9 g/dL (may have been transfused)
- •o Total bilirubin level = 1.5 × the upper limit of normal (ULN)
- •o ALT and AST = 2.5 × ULN (for subjects with documented metastatic disease to the liver: = 5 x ULN)
- •o Estimated creatinine clearance = 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method)
- •No active or chronic infection with HIV, Hepatitis B or C
- •Negative serum pregnancy test for women of childbearing potential
- •Highly effective contraception for both male and female patients throughout the study and for at least 30 days after last dose of study medication administration if the risk of conception exists. Highly effective contraception has to be in line with the definition of the CTFG (Clinical Trial Facilitation Group) recommendation (see 18.7)
- •Signed written informed consent and capacity of understanding the informed consent
排除标准
- •Patients will be excluded from the study for any of the following reasons:
- •Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v5.0 Grade = 3)
- •Patients with brain metastases
- •Current use of immunosuppressive medication, EXCEPT for the following:
- •o Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection)
- •o Systemic corticosteroids at physiologic doses = 10 mg/day of prednisone or equivalent
- •o Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
- •Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible.
- •Active infection requiring systemic therapy
- •Known history of testing positive for HIV or known acquired immunodeficiency syndrome
- •Vaccination with any live vaccine (e.g. intranasal flu vaccine) within 4 weeks before the first dose of avelumab or planned vaccination with live vaccine during the trial
- •Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (= New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication
- •Current other malignancies, except
- •o malignancies NOT requiring therapy such as B-CLL
- •o adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal carcinoma of the skin
- •Other severe acute or chronic medical conditions including colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study
- •Radiotherapy within 14 days prior to first dose of study treatment with the exception of palliative bone-directed radiotherapy, or radiotherapy administered on non-target superficial lesions
- •Any other systemic anti-tumor therapy in the last 4 weeks
- •Patients who discontinued prior check-point inhibitor therapy due to adverse reactions
- •Major surgery (excluding prior diagnostic biopsy) within 28 days prior to first dose of study treatment
- •Cytokine therapy (except erythropoietin) within 28 days prior to first dose of study treatment
- •Persisting toxicity related to prior therapy (NCI CTCAE v. 5.0 Grade > 1); however, alopecia, sensory neuropathy Grade = 2, or other Grade = 2 not constituting a safety risk based on investigator’s judgment are acceptable
- •Currently participating in or having participated in the treatment phase of a study of an investigational agent or using an investigational device within 4 weeks before registration and/or during study participation
- •Pregnancy or lactation period
- •Medical or psychological conditions that would not permit the patient to complete the study or sign informed consent
- •Known alcohol or drug abuse
- •Legal incapacity or limited legal
研究者
相似试验
进行中（未招募）
1 期
A study to test activity and safety of treatment with avelumab in combination with cetuximab in patients suffering from non-operable squamous cell skin cancer.EUCTR2018-001708-12-DEAlcedis GmbH52
进行中（未招募）
1 期
A phase II clinical trial of avelumab in combination with pegylated liposomal doxorubicin in recurrent/metastatic endometrial cancerEUCTR2018-000843-14-ESGEICO (Grupo Español de Investigación en Cáncer de Ovario)48
进行中（未招募）
1 期
A Phase II open-label (non-blinded), single-arm (same treatment for all participants) multicenter trial of MP0250 plus bortezomib+dexamethasone in patients with multiple myeloma whose disease did not respond to/has recurred after standard treatmentsMultiple myeloma (MM) is a relatively rare (114 000 new cases worldwide in 2012, i.e. 0.8% of total cancer cases [Cancer Research UK Incidence Statistics 2016]) blood cancer for which there is no cure. Treatment options rather mitigate symptoms and defer end-stage disease. MM cells have a tendency to clonally evolve which results in development of drug resistance, and patients eventually relapse.MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10028231Term: Multiple myeloma in remissionSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10028233Term: Multiple myeloma without mention of remissionSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10067095Term: Multiple myeloma progressionSystem Organ Class: 100000004864EUCTR2016-002771-10-DKMolecular Partners AG54
进行中（未招募）
1 期
A Phase II open-label (non-blinded), single-arm (same treatment for all participants) multicenter trial of MP0250 plus bortezomib+dexamethasone in patients with multiple myeloma whose disease did not respond to/has recurred after standard treatmentsEUCTR2016-002771-10-CZMolecular Partners AG54
进行中（未招募）
1 期
A Phase II open-label (non-blinded), single-arm (same treatment for all participants) multicenter trial of MP0250 plus bortezomib+dexamethasone in patients with multiple myeloma whose disease did not respond to/has recurred after standard treatmentsMultiple myeloma (MM) is a relatively rare (114 000 new cases worldwide in 2012, i.e. 0.8% of total cancer cases [Cancer Research UK Incidence Statistics 2016]) blood cancer for which there is no cure. Treatment options rather mitigate symptoms and defer end-stage disease. MM cells have a tendency to clonally evolve which results in development of drug resistance, and patients eventually relapse.EUCTR2016-002771-10-PLMolecular Partners AG54